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Abstract
Objectives To analyse the value of cardiovascular magnetic
resonance (CMR)-derived myocardial parameters to differ-
entiate left ventricular non-compaction cardiomyopathy
(LVNC) from other cardiomyopathies and controls.
Methods We retrospectively analysed 12 patients with
LVNC, 11 with dilated and 10 with hypertrophic cardiomy-
opathy and compared them to 24 controls. LVNC patients had
to fulfil standard echocardiographic criteria as well as addi-
tional clinical and imaging criteria. Cine steady-state free
precession and late gadolinium enhancement (LGE) imaging
was performed. The total LV myocardial mass index (LV-
MMI), compacted (LV-MMIcompacted), non-compacted (LV-
MMInon-compacted), percentage LV-MMnon-compacted, ventricu-
lar volumes and function were calculated. Data were com-
pared using analysis of variance and Dunnett’s test.
Additionally, semi-quantitative segmental analyses of the oc-
currence of increased trabeculation were performed.
Results Total LV-MMInon-compacted and percentage LV-
MMnon-compacted were discriminators between patients with
LVCN, healthy controls and those with other cardiomyopa-
thies with cut-offs of 15 g/m2 and 25 %, respectively.
Furthermore, trabeculation in basal segments and a ratio of
non-compacted/compacted myocardium of ≥3:1 were crite-
ria for LVNC. A combination of these criteria provided
sensitivities and specificities of up to 100 %. None of the
LVNC patients demonstrated LGE.
Conclusions Absolute CMR quantification of the LV-
MMInon-compacted or the percentage LV-MMnon-compacted and
increased trabeculation in basal segments allows one to
reliably diagnose LVNC and to differentiate it from other
cardiomyopathies.
Key Points
• Cardiac magnetic resonance imaging can reliably diag-
nose left ventricular non-compaction cardiomyopathy.
• Differentiation of LVNC from other cardiomyopathies and
normal hearts is possible.
• The best diagnostic performance can be achieved if com-
bined MRI criteria for the diagnosis are used.
Keywords Isolated non-compaction of the ventricular myo-
cardium .Magnetic resonance imaging . Ventricular
dysfunction, left . Cardiomyopathies
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Introduction
Left ventricular non-compaction (LVNC) is a rare cardio-
myopathy characterised by numerous excessively prominent
left ventricular (LV) trabeculation and deep intertrabecular
recesses communicating with the ventricular cavity and
severely altering myocardial structure. [1–3]. Although most
authors assume a developmental arrest in embryogenesis as
the underlying pathology [4, 5], the mechanisms of LVNC
are not fully understood yet. Several gene mutations have
been identified to be linked with LVNC and an autosomal
dominant inheritance mode is frequent [6–9].
To date the most commonly used imaging tool for diagnos-
ing LVNC is echocardiography applying the criteria estab-
lished by Jenni and co-authors [2]. However, qualitative or
even semi-quantitative parameters to differentiate normal com-
paction of the myocardium in healthy subjects from LVNC or
from other cardiomyopathies like dilated cardiomyopathy
(DCM) or hypertrophic cardiomyopathy (HCM) may fail be-
cause of highly variable LV trabeculation. Therefore, absolute
quantification should be performed. Cardiovascular magnetic
resonance (CMR) has been reported as a promising imaging
modality to characterise patients with LVNC as it provides
both a high spatial resolution and a good contrast between
trabeculation and blood pool [10, 11]. Jacquier et al. recently
reported that a value of non-compacted LV myocardial mass
above 20 % of the global mass of the LV is highly sensitive
and specific for LVNC [12]. However, in their approach, a
substantial degree of the LV cavity was included in the calcu-
lated trabecular LV mass and led to systemic overestimation of
the latter. Furthermore, no late gadolinium enhancement (LGE)
imaging was performed in their work, which has been de-
scribed as a potential prognostic factor in LVNC patients [13].
The aim of our retrospective study was to present improved
quantitative CMR criteria to distinguish LVNC from DCM,
HCM and a group of healthy controls, to add new qualitative
and semi-quantitative criteria, and to analyse the occurrence of
LGE in LVNC. We hypothesise that CMR can be used to
diagnose LVNC with high sensitivity and specificity and can
further help to differentiate LVNC from DCM and HCM.
Materials and methods
This overall retrospective study was approved by the local
ethics committee and complies with the Declaration of Hel-
sinki. All patients or parents gave written informed consent
for use of their anonymised data. Data of the control group
were assessed prospectively with a separate ethics commit-
tee approval. None of the authors received funding.
Patient population, control group and study design
Within a period of 60 months, 12 patients (3 male, 27 %)
with LVNC were included in the study. These patients had
to fulfil the echocardiographic criteria of Jenni [2]. Further-
more, to increase the probability of the diagnosis LVNC,
these criteria had to be accompanied by the following addi-
tional clinical and imaging findings as described before
[11]: (1) suspicion or confirmed diagnosis of LVNC in first
degree relatives, (2) associated neuromuscular disorders and
(3) complications such as systemic embolisation and/or
regional wall motion abnormalities or ventricular tachycardias
with or without syncopal attacks. A summary of the additional
Table 1 Additional findings in
LVNC patients
LVNC left ventricular non-
compaction, M male, F female,
VT ventricular tachycardia,
WMAwall motion abnormalities,
NM neuromuscular
LVNC
patients
Age
(years)
Gender Symptoms VT Family
history
Regional
WMA
NM
findings
1 14 M − + − −
2 11 F − + − −
3 27 M + − + −
4 51 F Syncope + − − −
5 33 F − − + −
6 43 F − − + −
7 42 F + − + −
8 43 F − − + −
9 71 M Syncope − − − −
10 16 F + − + −
11 27 F + − + −
12 39 F + − − −
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findings is given in Table 1. Exclusion criteria were an associ-
ated congenital or acquired heart disease and usual CMR con-
traindications such as implanted defibrillators/pacemakers.
Of the 12 included patients 8 initially presented with symp-
toms of heart failure. Three patients came for diagnostic eval-
uation of tachycardias, which were associated with syncopes in
two patients. Of two patients with a familial anamnesis, one
was clinically asymptomatic and came for screening.
CMR was performed within 3 days after echocardiogra-
phy. None of the patients fulfilled exclusion criteria for
CMR such as implanted defibrillators/pacemakers or intra-
cranial metallic implants.
We furthermore retrospectively included 10 consecutive
patients (4 male, 36 %) with HCM and 11 consecutive
patients (3 male, 27 %) with DCM that underwent CMR
within a period of 6 months. The diagnosis of HCM and
DCM was established on clinical, echocardiographic and
electrocardiographic criteria [14].
Patient parameters were compared to a gender-balanced
control group of 24 healthy volunteers without history of
cardiovascular disease and without clinical symptoms. Data
of the control group were assessed prospectively and sepa-
rately from the acquisition of the patient data covered by a
separate ethics committee approval.
Patient and control group characteristics are presented in
Table 2.
Genetic analysis
Two patients with familial LVNC underwent genetic analy-
ses. Pedigree analyses indicated an autosomal dominant
mode of inheritance. Exonic regions of six sarcomeric genes
were analysed by single-stranded conformational polymor-
phism, denaturing gradient gel electrophoresis or direct cycle
sequencing as previously described [7, 15]. The following
genes were analysed in the respective index patients: troponin
T, myosin binding protein C, alpha and beta myosin heavy
chain, lamin A/C and phospholamban.
Cardiovascular magnetic resonance
All CMR examinations were performed on a 1.5-T scanner
(Intera CV, Philips Healthcare, Best, the Netherlands) in
supine position using a dedicated 5-channel phased array
surface cardiac coil. Black-blood images with a slice thick-
ness of 8 mm in axial orientation were acquired to visualize
morphology. For volumetric and functional imaging, breath
hold standard cine steady-state free precession sequences in
short-axis 4-chamber view and LV vertical long-axis orien-
tation were acquired covering the whole heart gapless from
the apex to the base with a temporal resolution of 46 ms.
Echo time was 1.8 ms, repetition time 3.6 ms, flip angle 50°,
typical in-plane resolution was 1.7×1.8 mm, slice thickness
8 mm. LGE images in short-axis orientation were acquired
for quantification of fibrosis 10–15 min after application of
0.2 mmol/kg/body weight gadopentetate dimeglumine
(Magnevist, Bayer HealthCare Pharmaceuticals, Berlin,
Germany) using a three-dimensional T1-weighted inversion
recovery turbo gradient echo sequence. Echo time was
1.5 ms, repetition time 2.8 ms, flip angle 15°, typical in-
plane resolution 1.8×2 mm, slice thickness 8 mm.
Image analysis
CMR image analysis was performed by two fully blinded
observers, M.Gr. with 13 years and M.P. with 5 years of
experience in CMR, on a standard personal computer in a
random order in our CMR laboratory, which has expertise in
imaging of congenital heart disease and has proven low
intra- and interobserver variability for the assessment of
cardiac biventricular volumes and function [16, 17]. The
CAAS MRV software (Version 3, Pie-Medical Imaging,
Maastricht, Netherlands) was used for contouring com-
pacted and non-compacted myocardium. The algorithm
has been previously described in detail [18]. In brief, LV
epicardial borders were manually traced in end-systole and
end-diastole in 4-chamber view and vertical long-axis view
orientation. Registration marks were set at the level of the
mitral valve and the apex. For LV segmentation a contour
propagation algorithm based on the concept of fuzzy objects
and “hanging togetherness” throughout the short-axis
images was then performed [19]. In end-diastole, trabecula-
tion that was not included in the automated segmentation
was manually traced and marked with different colours than
the compacted myocardium allowing for assessment of total
Table 2 Demographic data
Controls LVNC HCM DCM
Number male/female 11/13 3/9 4/6 3/8
Age at examination (years) 20.2±6.3 (P00.01) 34.8±18.0 53.3±13.9 (P00.02) 32.6±17.0 (P00.92)
Body weight (kg) 65.0±10.4 (P00.52) 70.1±16.6 72.7±10.9 (P00.69) 75.4±18.0 (P00.90)
Body surface area (m2) 1.8±0.2 (P00.94) 1.8±0.2 1.9±0.2 (P00.75) 1.9±0.3 (P00.54)
Continuous data are presented as mean ± SD. P values in comparison with LVNC patients
LVNC left ventricular non-compaction, HCM hypertrophic cardiomyopathy, DCM dilated cardiomyopathy
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LV myocardial mass index (LV-MMI), the compacted (LV-
MMIcompacted), non-compacted (MMInon-compacted) and per-
centage LV-MMnon-compacted (Fig. 1a). During end-systole
(Fig. 1b) trabeculation is usually compressed which limits
the differentiation between non-compacted and compacted
myocardium. For calculation of the myocardial mass the
Fig. 1 a Assessment of non-compacted (pink contours) and com-
pacted (red and blue contours) left ventricular myocardium using
CAAS MRV software in controls, patients with left ventricular non-
compaction cardiomyopathy (LVNC), dilated cardiomyopathy (DCM)
and hypertrophic cardiomyopathy (HCM). Basal, midventricular and
apical cine steady-state free precession images in short-axis orientation
during end-diastole (echo time 1.8 ms, repetition time 3.6 ms, flip
angle 50°). All masses were assessed in end-diastole. bMidventricular
steady-state free precession (SSFP) images in short-axis orientation in
end-systole. In this phase trabeculation is compressed which makes it
almost impossible to differentiate non-compacted from compacted
myocardium. Therefore, the end-systolic phase is not suitable either
for measuring the ratio of non-compacted/compacted myocardium or
for quantifying the amount of non-compacted myocardium. Further-
more, this may also lead to an overestimation of LV ejection fractions
(EF) in LVNC and HCM patients
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specific density of 1.05 g/ml was used. Additionally, LV
end-diastolic volumes, end-systolic volumes, stroke vol-
umes and ejection fractions were calculated. All volumetric
measurements were performed twice by M.Gr. to measure
intraobserver variability and once by M.P. to measure inter-
observer variability. Absolute parameters were normalized
for body surface area [20].
We furthermore performed a semi-quantitative analysis of
trabeculated segments (TS) according to the 17-segment model
[21] for the occurrence of increased trabeculation of the LV.
The degree of trabeculated myocardium was measured in end-
diastole in short-axis orientation (segment 17 in the 4-chamber
view orientation) and the ratio was calculated. To simplify the
assessment of the segmental degree of non-compacted myocar-
dium for practical reasons it was categorised into four grades:
& No trabeculation
& Non-compacted/compacted myocardium ratio of <2:1
& Non-compacted/compacted myocardium ratio of ≥2:1 to
<3:1
& Non-compacted/compacted myocardium ratio of ≥3:1
To enable comparison with previously published data
[11], we additionally used the cut-off value of non-
compacted/compacted myocardium of >2.3:1 for categori-
sation and calculated the different statistical parameters
including and excluding segment 17, which can usually
not be assessed by echocardiography (Table 4).
Statistics
Categorical variables are expressed as number and percentage.
Continuous variables are given as mean ± standard deviation
according to normal distribution of data in the Kolmogorov–
Smirnov test. For comparison of means between the LVNC
group and the other groups a univariate analysis of variance
(ANOVA) in combination with Dunnett’s test was performed.
The categorical data of the segmental analysis were analysed
using the chi-square test or Fisher’s exact test. The intraob-
server variability was analysed by calculating the coefficient
of variation. Receiver operating characteristics (ROC) curves
were used to determine optimal cut-off values for distinguish-
ing LVNC from DCM, HCM and controls. Sensitivities, spe-
cificities, positive and negative prognostic values were
calculated for the criteria diagnosing LVNC. The tests were
performed as two-sided at a significance level α00.05. For
statistical analysis SPSS software version 16.0 (SPSS Inc.,
Chicago, Il, USA) was used.
Results
In one LVNC patient image quality was impaired in the cine
sequence because of breathing artefacts and no contour detec-
tion could be performed. This patient was excluded from
volumetric analysis but included in the analysis of TS. No
adverse events occurred. Patient and control group demo-
graphic data are presented in Table 2. Distribution of patient
and control group parameters is summarised in Table 3.
The LVNC group was significantly older than the control
group and younger than the HCM group (Table 2). Muta-
tional analysis did not identify mutations in the six sarco-
mere genes that were screened.
Volumetric parameters and myocardial mass
In LV volumetry, 5 of the remaining 11 LVNC patients had a
normal LV-EF of above 55 % according to published refer-
ence values [22]. Only one LVNC patient presented with
significant LV enlargement, which was associated with an
impaired LV-EF of 30 %. Total LV-MMInon-compacted and
percentage LV-MMnon-compacted were significantly increased
Table 3 Left ventricular volumes, masses and function
Controls LVNC HCM DCM
n024 n012 n010 n011
LV end-diastolic volume index (ml/m2) 84.2±12.6 (P00.99) 83.5±29.3 59.5±17.0 (P00.045) 99.1±21.7 (P00.23)
LV end-systolic volume index (ml/m2) 34.8±7.9 (P00.03) 42.5±26.1 16.1±6.1 (P00.09) 44.3±22.9 (P00.53)
LV stroke volume index (ml/m2) 49.3±9.4 (P00.57) 41.4±13.6 43.4±16.5 (P00.64) 54.9±12.0 (P00.36)
LV ejection fraction (%) 58.4±8.1 (P00.05) 50.8±16.1 71.7±9.9 (P00.01) 56.9±14.7 (P00.05)
Total LV-MMI (g/m2) 53.5±10.3 (P<0.01) 87.3±26.9 85.6±22.4 (P00.98) 54.7±16.3 (P00.01)
LV-MMIcompacted (g/m
2) 48.0±9.6 (P00.24) 55.7±19.9 78.7±21.5 (P00.01) 50.3±15.0 (P00.70)
LV-MMInon-compacted (g/m
2) 5.3±2.4 (P<0.001) 31.6±11.1 7.0±3.1 (P<0.001) 4.4±2.0 (P<0.001)
Percentage LV-MM non-compacted (%) 9.9±4.4 (P<0.001) 36.4±10.9 8.4±4.2 (P<0.001) 7.9±2.9 (P<0.001)
Continuous data are presented as mean ± SD. P values in comparison with LVNC patients
LVNC left ventricular non-compaction, HCM hypertrophic cardiomyopathy, DCM dilated cardiomyopathy, LV left ventricular, MMI myocardial
mass index, MM myocardial mass
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in LVNC and are good discriminators between patients with
LVNC and all other cardiomyopathies and controls (P<
0.001 for all, Table 3).
For diagnosing LVNC ROC curves revealed optimal cut-
off values of 25 % for percentage LV-MM non-compacted (1st
criterion) and 15 g/m2 total LV-MMI non-compacted (2nd cri-
terion) (Fig. 2, Table 4). Intraobserver variability for assess-
ment of myocardial masses and volumetric parameters using
the CAAS software was low with a mean difference of
3.1 %. The coefficient of variation was less than 2 for all
measurements with a mean value of 1.25±3.4 %. Interob-
server variability was higher with a mean difference of
5.7 % and a coefficient of variation of 4.2±2.2.
Late gadolinium enhancement (LGE)
None of the LVNC patients demonstrated intramyocardial
LGE. In contrast, LGE was found in all other patients. Of 10
HCM patients 8 presented with a patchy enhancement of the
interventricular septum. Two HCM patients showed patchy,
partly confluent enhancement also in the anterior wall.
In DCM hyperenhancement was also located in the inter-
ventricular septum in most cases. Nine of 11 patients demon-
strated a streaky midwall LGE in the interventricular septum.
In 3 patients this enhancement extended to the inferior wall.
Analysis of trabeculated segments (TS)
The analysis of trabeculation patterns demonstrated the spe-
cifics of LVNC patients with regard to number and distri-
bution of TS. LVNC patients demonstrated an average of
12.6±1.6 TS ,whereas the number was much lower in HCM
patients (6±1.2, P<0.001), DCM patients (4.5±0.9, P<
0.001) and controls (5.0±1.4, P<0.001). Analysis of the
TS distribution revealed that in the LVNC group each seg-
ment showed trabeculation at least once but not in the DCM,
HCM and control groups (Fig. 3a). In particular, the basal and
septal segments 4–6 were trabeculated more frequently in
LVNC patients. Also the degree of trabeculation was higher
compared with HCM, DCM and controls (Fig. 3a). Even in
the basal segments 1–6, which showed only little trabeculation
in any of the other patients or controls, we found some LV-
MMInon-compacted /LV-MMIcompacted ratios of ≥3:1.
Therefore, a ratio of non-compacted/compactedmyocardium
of ≥3:1 (3rd criterion) in at least one of the other segments (1–3,
7–16) showed a very high sensitivity of 100% and specificity of
93 % as well as a very high NPVof 100 % (Table 4). If segment
17 was included the specificity decreased to 73 %.
Furthermore, an LV-MMInon-compacted /LV-MMIcompacted
ratio ≥2:1 in the basal segments 4–6 was highly specific
for the diagnosis of LVNC (4th criterion).
Applying the recently published cut-off value of >2.3:1 [11]
to our study cohort and excluding segment 17 we obtained a
sensitivity of 100 % but specificity was only 80 %. When
including segment 17, the specificity further decreases (Table 4).
Combined criteria
The best diagnostic performance, which means the best
compromise between a high sensitivity and specificity as
well as a high PPV and NPV, could be achieved if a com-
bined criteria approach for the diagnosis of the four identi-
fied single MRI parameters was used, especially when using
the criterion that at least three of the four identified MRI
criteria had to be positive for LVNC (Table 4).
Discussion
There is no specific treatment for LVNC. Nevertheless, the
early and precise diagnosis is mandatory to rule out other
underlying diagnoses and to allow a timely start of standard
heart failure and anticoagulation therapy which may prevent
further complications.
Fig. 2 Receiver operating characteristic (ROC) curves showing the
sensitivity and specificity of left ventricular non-compacted myocardial
mass index (a) and percentage non-compacted myocardial mass (b) for
diagnosing left ventricular non-compaction cardiomyopathy. Both
parameters demonstrate excellent AUC values of 0.99. Cut-off values
of 15 g/m2 and 25 % afford comparable sensitivities of 91 % and
specificities of up to 100 %
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Our study provides redefined and extended CMR criteria
for diagnosing and discriminating LVNC from other cardio-
myopathies. These four basic criteria are (Table 4)
1. Percentage LV-MMnon-compacted >25 %
2. Total LV-MMInon-compacted >15 g/m
2
3. Non-compacted/compacted myocardium ratio of ≥3:1 in
at least one of the other segments (1–3, 7–16) excluding
the apical segment 17
4. Trabeculation in segments 4–6≥2:1 (non-compacted/
compacted)
There are some studies using echocardiographic criteria
for diagnosing LVNC [2, 5]. However, this approach is
highly investigator-dependent, diagnosis is based on two-
dimensional planes using semi-quantitative or qualitative
criteria and specificity is low [23]. Two-dimensional CMR
criteria derived from echocardiography [11, 24] offer a
better visualization of all regions of the LV but suffer from
the same fundamental limitations. One major advantage of
CMR is the three-dimensional approach, which allows for
imaging of the entire volume of the heart with lower inves-
tigator dependency and without limitations caused by a
patient’s constitution. Our results demonstrated a good
reproducibility with low intra- and interobserver variability.
Jacquier et al. [12] were first to measure the total amount of
trabeculation and to propose a cut-off value above which the
diagnosis of LVNC is likely. However, in their study endo-
cardial contours were traced along the tip of LV trabecula-
tion towards the LV cavity and therefore intertrabecular
blood pool was included in the trabeculated mass, especially
in LVNC patients.
In the present study we tried to overcome these limita-
tions by excluding blood pool from the assessment of LV-
MMInon-compacted. Additionally the purpose of this study was
to analyse the occurrence of LGE in LVNC.
We performed genetic analysis in two patients in
which, however, mutation screening was negative. A
recent work showed that the LVNC patients with muta-
tions in sarcomere genes are phenotypically not distinct
from those without a mutation [25]. A negative genetic
analysis of six sarcomere genes, like in our study, does
therefore not rule out the diagnosis of LVNC. There is a
wide variety in the location of the gene mutation, which
can make the effort required for genetic analysis unrea-
sonably high. The pedigree analyses are more often
helpful and indicated an autosomal dominant mode of
inheritance in these two patients.
Table 4 Impact of criteria
Criteria met Sensitivity 95 % CI Specificity 95 % CI PPV NPV
Single criteria
1. Percentage LV- MMnon-compacted>25 % 91 62.3–98.4 100 92.1–100 100 98
(10/11) (45/45) (10/10) (45/46)
2. Total LV-MMInon-compacted>15 g/m
2 91 62.3–98.4 91 79.3–96.5 71 98
(10/11) (41/45) (10/14) (41/42)
3. Cut-off≥3:1 (segment 17 excluded) 100 75.8–100 93 82.1–97.7 80 100
(12/12) (42/45) (12/15) (42/42)
4. Trabeculation in segments 4–6≥2:1 67 39.1–86.2 91 79.3–96.5 67 91
(8/12) (41/45) (8/12) (41/45)
Cut-off≥3:1 (segment 17 included) 100 75.8–100 73 59.0–84.1 50 100
(12/12) (33/45) (12/24) (33/33)
Cut-off>2.3:1 (segment 17 excluded) 100 75.8–100 80 66.2–89.1 57 100
(12/12) (36/45) (12/21) (36/36)
Cut-off>2.3:1 (segment 17 included) 100 75.8–100 58 43.3–71.0 39 100
(12/12) (26/45) (12/31) (19/19)
Combined criteria (1–4)
Two of four criteria (1–4) 100 75.8–100 95 85.2–98.8 86 100
(12/12) (43/45) (12/14) (43/43)
Three of four criteria (1–4) 92 64.6–98.5 100 92.1–100 100 96
(11/12) (45/45) (9/9) (45/48)
Four of four criteria (1–4) 75 46.8–91.1 100 92.1–100 100 94
(9/12) (45/45) (7/7) (45/49)
Sensitivity and specificity data are presented as percentage with number of related patients in parenthesis
CI confidence interval, PPV positive predictive value, NPV negative predictive value
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Mass and distribution of LV trabeculation
Compared with Jaquier et al. results [12], our study shows
some discrepancies in regard to LV volumes and masses.
LV-MMInon-compacted was lower in all patient groups and
controls in the present study, which is most likely the result
of the exclusion of blood pool. However, percentage LV-
MMnon-compacted of LVNC patients was similar, meaning that
LV-MMIcompacted was lower in our group. This might be
explained by the female predominance in our LVNC cohort
(Table 2). In the same group we also found a lower LV-
EDVI; however, our group was younger and presented with
an LV-EF within a lower normal range (Table 3) compared
with the clearly impaired LV function of the LVNC cohort
of the cited study. The aforementioned differences result in a
minor discrepancy of the percentage LV-MMnon-compacted
(25 % vs. 20 %). Nevertheless, both studies clearly demon-
strate that it is possible to diagnose LVNC using this pa-
rameter. The distinct assessment of LV trabeculation in the
present study additionally allows for introduction of a total
Fig. 3 Percentage, distribution and degree of trabeculated segments of
the left ventricular myocardium of the different patient cohorts and
healthy controls. Segmentation according to the 17-segment model of
the American Heart Association. Legend shows the ratio of non-
compacted/compacted myocardium. The distribution of trabeculation
according to the classification of the present study is shown in a. The
distribution according to the previously published cut-off of >2.3:1 is
shown in b. Note the exclusive occurrence of a≥3:1 trabeculation in
the basal segments in LVNC patients and the overlap with other
diseases, especially HCM but also DCM in the apical segments
Fig. 4 Box plot diagram demonstrating the highly significant differences
of left ventricular non-compacted myocardial mass index in controls, left
ventricular non-compaction cardiomyopathy (LVNC), hypertrophic car-
diomyopathy (HCM) and dilatative cardiomyopathy (DCM)
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LV-MMInon-compacted cut-off value of 15 g/m
2 (Fig. 4), mak-
ing it is possible to diagnose LVNC independently of the
mass of the compacted myocardium.
According to literature data, the distribution of TS in
LVNC is controversial. In a large echocardiographic study
with 34 patients the authors found TS in the midventricular
and apical segments [26]. Jacquier et al. did not find a
specific distribution of TS in LVNC patients compared to
DCM, HCM and controls [12]. In the present study we
could demonstrate that trabeculation in the segments 4–6
(Fig. 5) alludes to a high probability for LVNC (Fig. 3a).
Only one HCM patient also showed trabeculation in these
segments with a ratio of non-compacted/compacted myo-
cardium of <2:1. As demonstrated in Fig. 3a the degree of
trabeculation can also be considered as a good discriminator
between LVNC and the other patient cohorts and controls.
In the LVNC cohort the number of segments with a non-
compacted/compacted myocardium ratio of ≥3:1 is highest
by far not only in the basal and midventricular but also in
the apical segments. The use of a myocardial compacted/
non-compacted ratio is a common criterion for diagnosis of
LVNC in both echocardiographic and CMR studies. How-
ever, there is controversy regarding the ratio value and
whether it should be measured in end-systole or end-
diastole. Petersen et al. considered a CMR ratio between
the non-compacted and the compacted layer of >2.3:1 diag-
nostic for LVNC [11]. Applying this ratio to our study
cohort (Fig. 3b) we achieved sensitivities of 100 % and
Fig. 5 Steady-state free precession basal short-axis view (echo time
1.8 ms, repetition time 3.6 ms, flip angle 50°) demonstrating a ratio of
non-compacted/compacted myocardium of almost 3:1 in segment 4.
Orange line represents compacted myocardium, white line represents
non-compacted myocardium
Fig. 6 Late gadolinium enhancement (LGE) images (a–c) with typical
enhancement patterns of hypertrophic cardiomyopathy (HCM) and
dilated cardiomyopathy (DCM). Steady-state free precession (SSFP)
images during end-systole (d–f) and end-diastole (g–i) of a typical left
ventricular non-compaction (LVNC), HCM and DCM patient
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specificities of 80 % (excluding segment 17) or 58 % (in-
cluding segment 17). The specificities were much lower
than in the cited study and also lower as compared to our
single or combined criteria we propose (Table 4). Further-
more, the PPV was only 57 % and 39 % respectively. In the
present study we found many HCM and DCM patients with
a non-compacted/compacted ratio between 2:1 and 3:1. Of
these some had a ratio of >2.3:1. These patients impair the
specificity of the cited cut-off value as too many HCM and
DCM patients have false positive results for LVNC.
The discrepancy between the study results could be caused
by a different approach in the measurement of the thickness of
compacted and non-compacted myocardium. Petersen et al.
[11] used three long-axis views, whereas in our study short-
axis views were used (except for segment 17).
A second possible explanation might be differences in the
HCM and DCM patient cohorts; however, no details about
these patients are provided in Petersen et al.’s report [11].
LVNC and LGE
None of our LVNC patients presented with myocardial LGE
(Fig. 6). Our findings are in line with other studies that also
stated a lack of LGE in LVNC [27, 28]. On the other hand,
there are also studies that do report LGE findings [13,
29–31].
The reasons for these discrepancies remain unclear. First-
ly, the presence or absence of LGE does probably not
depend on patient age as the mean age of our LVNC cohort
without LGE (35 years) is framed by the mean ages of two
patient groups with positive LGE [13, 31]. Secondly, there
was no significant difference in the mean LV ejection frac-
tion between our LVNC patients and the patients of one
study [13]. Finally all cited imaging studies were performed
using 1.5-T MR systems. However, the authors of the larg-
est cited study [13] used a T1-weighted inversion recovery
gradient echo sequence, depending on correct adjustments
of inversion time [32], whereas a smaller study without
positive LGE findings in LVNC patients used a more mod-
ern phase-sensitive inversion recovery sequence, which has
shown advantages in visualisation of fibrosis in regard to
image quality and reproducibility compared with standard
magnitude detection [33]. Therefore, the contradictory LGE
findings in the present and the cited studies might be partly
caused by differences in imaging techniques.
The described macroscopic LGE patterns in LVNC
patients varied substantially from subendocardial, transmu-
ral, intramyocardial to subendocardial [13, 30] and no spe-
cific or at least typical enhancement patterns for LVNC
patients have been described so far. Therefore, especially
in the adult group, an additional underlying coronary artery
disease or e.g. postinflammatory changes causing different
patterns of LGE described in LVNC patients have to be
excluded to be sure that the macroscopic LGE is indeed an
intrinsic finding of LVNC and not an epiphenomenon
caused by other coexisting diseases.
The absence of LGE in our study cohort better corre-
sponds with the theory of a developmental arrest [4, 5] as
the underlying pathophysiology of LVNC than with the
competing theory of a traumatic or ischemic pathophysiol-
ogy [34]. According to the latter theory one would expect
scar tissue and typical patterns of LGE in each LVNC
patient. In developmental arrest though, caused by a genetic
mutation, the absence of such alterations would not be
contradictory. However, this might be a premature conclu-
sion as the LGE technique might just overlook some cases
of fibrosis as a result of the given spatial resolution.
The presence, pathophysiology and meaning of LGE in
LVNC patients need to be confirmed by further studies with
a genetic diagnosis and a larger sample size to increase
statistical power and to potentially identify risk factors for
developing fibrosis in LVNC.
Limitations
Genetic analysis was performed only in two LVNC patients
with familial disease. However, no gene mutation could be
identified indicating that other genes may be involved in the
genetic aetiology of LVNC. A cohort of LVNC patients with
a genetic diagnosis would increase the reliability of a CMR-
derived diagnosis.
Owing to the prevalence of LVNC the study population
was small in terms of statistical means. Multicentre studies
are necessary to confirm our findings in a larger patient
cohort.
Furthermore, CMR follow-up examinations would be
helpful to assess a potential change of non-compacted or
compacted mass in a chronological sequence.
In conclusion, CMR can distinguish LVNC from other
cardiomyopathies and normal hearts with high sensitivity
and specificity. In our study we introduce highly reproduc-
ible volumetric cut-off values and two semi-quantitative
criteria. The role of the absence or presence of LGE in
LVNC has to be further investigated.
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